NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bladder cancer patients: early access to TAR-200
Disease control APPROVED_FOR_MARKETINGThis program offers early access to TAR-200, an experimental treatment, for people with high-risk non-muscle invasive bladder cancer who have run out of standard options. Participants must have tried all other treatments and cannot join a clinical trial. The goal is to provide tr…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New bladder cancer device aims to delay surgery in High-Risk patients
Disease control OngoingThis study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either cannot have or choose not to have their bladder removed. The study compares TAR-200 to standard chemotherapy placed …
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Pee test could spare bladder cancer patients painful scopes
Diagnosis OngoingThis study looks at whether a urine test called BladMetrix can safely detect bladder cancer coming back after surgery. About 500 adults with non-invasive bladder cancer will provide extra urine samples during their regular check-ups over two years. The goal is to see if the test …
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Oslo University Hospital • Aim: Diagnosis
Last updated May 15, 2026 11:57 UTC